NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1110 coverAutoimmunity, Part B Novel Applications of Basic Research Volume 1110 published September 2007
Ann. N.Y. Acad. Sci. 1110: 330–336 (2007). doi: 10.1196/annals.1423.035
Copyright © 2007 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by UYTTENHOVE, C.
Articles by VAN SNICK, J.
Search for Related Content
PubMed
PubMed Citation
Articles by UYTTENHOVE, C.
Articles by VAN SNICK, J.

Part II. Treatment

Anti-IL-17A Autovaccination Prevents Clinical and Histological Manifestations of Experimental Autoimmune Encephalomyelitis

CATHERINE UYTTENHOVEa,b, CAROLINE SOMMEREYNSc, IVAN THÉATEa,d, THOMAS MICHIELSc AND JACQUES VAN SNICKa,e

a Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium b Cellular Genetics Unit, Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium c Microbial Pathogenesis Unit, Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium d Department of Pathology, Université Catholique de Louvain, Brussels, Belgium e Experimental Medicine Unit, Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

Key Words: EAE • vaccine • cytokine • autoimmunity • Th17

Address for correspondence: Dr. C. Uyttenhove, Ludwig Institute for Cancer Research, Brussels Branch, 74 av. Hippocrate UCL 7459, B-1200 Brussels, Belgium. Voice: +32-2-764-74-18; fax: +32-2-762-94-05.  catherine.uyttenhove{at}bru.licr.org

Excessive or inappropriate production of IL-17A has been reported in diseases such as rheumatoid arthritis, asthma, and multiple sclerosis. The potential clinical relevance of these correlations was suggested by the protective effects of anti-IL-17A monoclonal antibodies in various mouse disease models. However, the chronic nature of the corresponding human afflictions raises great challenges for Ab-based therapies. An alternative to passive Ab therapy is autovaccination. Covalent association of self-cytokines with foreign proteins has been reported to induce the production of antibodies capable of neutralizing the biological activity of the target cytokine. We recently reported that cross-linking of IL-17A to ovalbumin produced highly immunogenic complexes that induced long-lasting IL-17A-neutralizing antibodies. Vaccinated SJL mice were completely protected against experimental autoimmune encephalomyelitis (EAE) induced by proteolipid protein peptide (PLP 139–151), and a monoclonal anti-IL-17A Ab (MM17F3), derived from C57Bl/6 mice vaccinated against IL-17A-OVA, also prevented disease development. Here we report that this Ab also protects C57Bl/6 mice from myelin oligdendrocyte glycoprotein (MOG)-induced EAE. Histological analysis of brain sections of C57Bl/6 mice treated with MM17F3 showed a complete absence of inflammatory infiltrates and evidence for a marked inhibition of chemokine and cytokine messages in the spinal cord. These results further extend the analytical and therapeutic potential of the autovaccine procedure.






footerLeft footerRight